Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
- PMID: 17242417
- DOI: 10.1194/jlr.C600025-JLR200
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism. We developed second generation antisense oligonucleotide (ASO) inhibitors targeting murine PCSK9 to determine their potential as lipid-lowering agents. Administration of a PCSK9 ASO to high fat-fed mice for 6 weeks reduced total cholesterol and LDL by 53% and 38%, respectively. Moreover, inhibition of PCSK9 expression resulted in a 2-fold increase in hepatic LDLR protein levels. This phenotype closely resembles that reported previously in Pcsk9-deficient mice. The absence of cholesterol lowering in Ldlr-deficient mice effectively demonstrated a critical role for this receptor in mediating the lipid-lowering effects of PCSK9 inhibition. Antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia in human.
Similar articles
-
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.PLoS One. 2010 May 17;5(5):e10682. doi: 10.1371/journal.pone.0010682. PLoS One. 2010. PMID: 20498851 Free PMC article.
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Review.
-
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20. Circulation. 2013. PMID: 23690465 Free PMC article.
-
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):157-68. doi: 10.1177/1074248414539562. Epub 2014 Jun 17. J Cardiovasc Pharmacol Ther. 2015. PMID: 24938457 Review.
-
The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Pharmacol Res. 2013 Jul;73:27-34. doi: 10.1016/j.phrs.2013.04.001. Epub 2013 Apr 8. Pharmacol Res. 2013. PMID: 23578522 Review.
Cited by
-
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD).Adv Pharm Bull. 2020 Sep;10(4):502-511. doi: 10.34172/apb.2020.062. Epub 2020 Aug 9. Adv Pharm Bull. 2020. PMID: 33062601 Free PMC article. Review.
-
Unveiling Familial Hypercholesterolemia-Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy.Int J Mol Sci. 2024 Jan 29;25(3):1637. doi: 10.3390/ijms25031637. Int J Mol Sci. 2024. PMID: 38338916 Free PMC article. Review.
-
Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.EXCLI J. 2022 Jan 5;21:47-76. doi: 10.17179/excli2021-4453. eCollection 2022. EXCLI J. 2022. PMID: 35221836 Free PMC article. Review.
-
Therapeutic RNA manipulation in liver disease.Hepatology. 2010 Mar;51(3):1055-61. doi: 10.1002/hep.23344. Hepatology. 2010. PMID: 19918970 Free PMC article. Review.
-
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.Scientifica (Cairo). 2012;2012:927352. doi: 10.6064/2012/927352. Epub 2012 Sep 11. Scientifica (Cairo). 2012. PMID: 24278757 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous